Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neuroendocrine tumor arising from the delta cells of the pancreas. It is characterized by inappropriate secretion of somatostatin and associated with diabetes mellitus, hypochlorhydria, gallbladder disease, diarrhea, steatorrhea, anemia, and weight loss.
Biomarker and diagnostic research for pancreatic somatostatinoma has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
51 publications have been identified in PubMed for pancreatic somatostatinoma. Research spans Review / Meta-Analysis (25%), Basic Science / Preclinical (25%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 13 | 25% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:13 AM UTC
Laboratory research |
13 |
25% |
Patient case studies | 8 | 16% |
New treatment approaches | 6 | 12% |
Testing and diagnosis research | 4 | 8% |
Clinical study results | 4 | 8% |
Disease patterns and progression | 3 | 6% |
Virgolini IJ (2026). [PMID: 41689648](https://pubmed.ncbi.nlm.nih.gov/41689648/). *European journal of nuclear medicine and molecular imaging*. [Review / Meta-Analysis]
Fu Y (2026). [PMID: 40934719](https://pubmed.ncbi.nlm.nih.gov/40934719/). *Annals of diagnostic pathology*. [Diagnostic / Biomarker]
Albalawi M (2026). [PMID: 42022489](https://pubmed.ncbi.nlm.nih.gov/42022489/). *JCEM Case Rep*. [Case Report / Case Series]
Wang F (2026). [PMID: 41919978](https://pubmed.ncbi.nlm.nih.gov/41919978/). *ACS Nano*. [Gene Therapy / Novel Therapeutics]
Cole Y (2026). [PMID: 41518596](https://pubmed.ncbi.nlm.nih.gov/41518596/). *The Journal of clinical endocrinology and metabolism*. [Epidemiology / Natural History]
Fedeli F (2026). [PMID: 41836257](https://pubmed.ncbi.nlm.nih.gov/41836257/). *Frontiers in oncology*. [Basic Science / Preclinical]
Mastoraki A (2026). [PMID: 41868867](https://pubmed.ncbi.nlm.nih.gov/41868867/). *Annals of gastroenterology*. [Review / Meta-Analysis]
Liu Z (2026). [PMID: 41676272](https://pubmed.ncbi.nlm.nih.gov/41676272/). *American journal of translational research*. [Clinical Trial Publication]
Lugat A (2025). [PMID: 39269657](https://pubmed.ncbi.nlm.nih.gov/39269657/). *European journal of nuclear medicine and molecular imaging*. [Basic Science / Preclinical]
Unknown (2025). [PMID: 41474856](https://pubmed.ncbi.nlm.nih.gov/41474856/). *Unknown Journal*. [Review / Meta-Analysis]